WO1998017319A3 - Platelet substitutes and conjugation methods suitable for their preparation - Google Patents

Platelet substitutes and conjugation methods suitable for their preparation Download PDF

Info

Publication number
WO1998017319A3
WO1998017319A3 PCT/GB1997/002877 GB9702877W WO9817319A3 WO 1998017319 A3 WO1998017319 A3 WO 1998017319A3 GB 9702877 W GB9702877 W GB 9702877W WO 9817319 A3 WO9817319 A3 WO 9817319A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
methods suitable
fibrinogen
conjugation methods
platelet substitutes
Prior art date
Application number
PCT/GB1997/002877
Other languages
French (fr)
Other versions
WO1998017319A2 (en
Inventor
David Heath
Sarah Margaret Middleton
Roy Harris
Nicola Jane Church
Original Assignee
Andaris Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26310263&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998017319(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9621886.2A external-priority patent/GB9621886D0/en
Priority claimed from GBGB9702652.0A external-priority patent/GB9702652D0/en
Priority to EP97909451A priority Critical patent/EP1028752B1/en
Priority to AT97909451T priority patent/ATE284714T1/en
Priority to JP51910098A priority patent/JP2001504813A/en
Application filed by Andaris Ltd filed Critical Andaris Ltd
Priority to DE69731985T priority patent/DE69731985T2/en
Priority to AU47135/97A priority patent/AU718956B2/en
Priority to DK97909451T priority patent/DK1028752T3/en
Priority to CA2269335A priority patent/CA2269335C/en
Publication of WO1998017319A2 publication Critical patent/WO1998017319A2/en
Publication of WO1998017319A3 publication Critical patent/WO1998017319A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Abstract

Platelet substitutes, comprising fibrinogen, or analogous products useful in therapy, comprise an insoluble carrier to which is bound an essentially non-degraded active protein including the sequence RGD. Such conjugates can be made by a conjugation process comprising 0.01 to 2.5 % by weight active fibrinogen, and no more than 50 % inactive fibrinogen.
PCT/GB1997/002877 1996-10-21 1997-10-17 Platelet substitutes and conjugation methods suitable for their preparation WO1998017319A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2269335A CA2269335C (en) 1996-10-21 1997-10-17 Platelet substitutes and conjugation methods suitable for their preparation
DK97909451T DK1028752T3 (en) 1996-10-21 1997-10-17 Platelet replacement preparations and conjugation methods suitable for their preparation
AU47135/97A AU718956B2 (en) 1996-10-21 1997-10-17 Platelet substitutes and conjugation methods suitable for their preparation
AT97909451T ATE284714T1 (en) 1996-10-21 1997-10-17 PLATE SUBSTITUTE AND SUITABLE CONJUGATION PRODUCTION METHOD
JP51910098A JP2001504813A (en) 1996-10-21 1997-10-17 Platelet substitutes and conjugation methods suitable for their production
EP97909451A EP1028752B1 (en) 1996-10-21 1997-10-17 Platelet substitutes and conjugation methods suitable for their preparation
DE69731985T DE69731985T2 (en) 1996-10-21 1997-10-17 BLANK SPARE PARTS AND SUITABLE CONJUGATION MANUFACTURING PROCESS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9621886.2 1996-10-21
GBGB9621886.2A GB9621886D0 (en) 1996-10-21 1996-10-21 Microparticles and their therapeutic use
GB9702652.0 1997-02-10
GBGB9702652.0A GB9702652D0 (en) 1997-02-10 1997-02-10 Conjugates and their preparation

Publications (2)

Publication Number Publication Date
WO1998017319A2 WO1998017319A2 (en) 1998-04-30
WO1998017319A3 true WO1998017319A3 (en) 1998-06-11

Family

ID=26310263

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/002877 WO1998017319A2 (en) 1996-10-21 1997-10-17 Platelet substitutes and conjugation methods suitable for their preparation

Country Status (10)

Country Link
US (1) US5977313A (en)
EP (1) EP1028752B1 (en)
JP (1) JP2001504813A (en)
AR (1) AR008680A1 (en)
AT (1) ATE284714T1 (en)
AU (1) AU718956B2 (en)
CA (1) CA2269335C (en)
DE (1) DE69731985T2 (en)
ES (1) ES2232862T3 (en)
WO (1) WO1998017319A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
CA2294494A1 (en) 1997-06-05 1998-12-10 Richard C. K. Yen Fibrinogen-coated microspheres
GB9724143D0 (en) 1997-11-14 1998-01-14 Andaris Ltd Pharmaceutical conjugate
EP1056484A1 (en) * 1998-02-20 2000-12-06 Quadrant Healthcare (UK) Limited Products comprising fibrinogen for use in therapy
GB9825105D0 (en) * 1998-11-16 1999-01-13 Andaris Ltd Pharamaceutical conjugates
GB9827813D0 (en) * 1998-12-17 1999-02-10 Andaris Ltd Pharmaceutical conjugates
DE19926475A1 (en) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Carrier-drug conjugates
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
DE10135356C1 (en) * 2001-07-20 2003-04-17 Schering Ag Macrocyclic metal complexes and their use for the preparation of conjugates with biomolecules
US7306925B2 (en) 2001-11-09 2007-12-11 Vanderbilt University Phage antibodies to radiation-inducible neoantigens
AU2002330139A1 (en) * 2001-10-03 2003-04-14 Vanderbilt University In vivo panning for ligands to radiation-induced molecules
US7906102B2 (en) 2001-10-03 2011-03-15 Vanderbilt University Ligands to radiation-induced molecules
GB0323378D0 (en) 2003-10-07 2003-11-05 Univ Leicester Therapeutic agent
GB0516091D0 (en) * 2005-08-04 2005-09-14 Haemostatix Ltd Therapeutic agent
US20080015145A1 (en) * 2006-07-11 2008-01-17 Maria Gyongyossy-Issa Mimotope receptors and inhibitors for platelet-platelet and platelet-endothelium interactions
GB0623607D0 (en) 2006-11-27 2007-01-03 Haemostatix Ltd Tissue adhesive
WO2009140598A1 (en) * 2008-05-16 2009-11-19 Bayer Healthcare Llc Targeted coagulation factors and method of using the same
WO2010136588A2 (en) 2009-05-28 2010-12-02 Profibrix B.V. Dry powder fibrin sealant
GB201101740D0 (en) * 2011-02-01 2011-03-16 Haemostatix Ltd Therapeutic agents with improved fibrinogen binding
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
GB201201751D0 (en) 2012-02-01 2012-03-14 Haemostatix Ltd Haemostatic wound dressing
US20130202675A1 (en) 2012-02-03 2013-08-08 Dynasil Biomedical Corporation Systems and methods for the fabrication of tissue patches
GB201204868D0 (en) 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
EP3172222A4 (en) 2014-07-24 2018-03-21 Washington University Compositions targeting radiation-induced molecules and methods of use thereof
US9833538B2 (en) 2015-08-07 2017-12-05 Xcede Technologies, Inc. Adhesive compositions and related methods
US9540548B1 (en) 2015-08-07 2017-01-10 Xcede Technologies, Inc. Adhesive compositions and related methods
AU2016307447A1 (en) 2015-08-07 2018-02-22 Xcede Technologies, Inc. Adhesive compositions and related methods
CN107686508B (en) * 2016-08-05 2021-02-12 首都医科大学 Adriamycin-RGDS, its synthesis, activity and application
CN107686507B (en) * 2016-08-05 2021-02-12 首都医科大学 RGDS-adriamycin, its synthesis, activity and application
EP3634459A4 (en) 2017-02-10 2021-01-06 Washington University Antibodies to tip1 and methods of use thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661471A (en) * 1984-04-10 1987-04-28 New England Deaconess Hospital Method of inhibiting and inducing human platelet aggregation
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4673573A (en) * 1984-01-11 1987-06-16 Beecham Group P.L.C. Novel fibrinolytic enzyme compounds
EP0283563A2 (en) * 1983-12-24 1988-09-28 Beecham Group Plc Novel derivatives
EP0333517A2 (en) * 1988-03-18 1989-09-20 The Rockefeller University Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
WO1990003401A1 (en) * 1988-09-30 1990-04-05 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
WO1992013547A1 (en) * 1991-02-07 1992-08-20 Alexander Mellon Eaton Drug delivery composition and method of using the same
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
EP0727225A2 (en) * 1995-02-14 1996-08-21 Sonus Pharmaceuticals, Inc. Compositions and methods for directed ultrasound imaging

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
EP0494417B1 (en) * 1991-01-10 1996-04-17 Basf Corporation Process for crosslinking gelatin and for incorporation a material therein
DK0495187T3 (en) * 1991-01-15 1997-08-11 Hemosphere Inc Protein nanomatrices and method of preparation.
WO1996039128A1 (en) * 1995-06-06 1996-12-12 Hemosphere, Inc. Protein particles for therapeutic and diagnostic use
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
WO1992013495A1 (en) * 1991-02-07 1992-08-20 Fibratek, Inc. Fibrinogen based adhesive
GB9107628D0 (en) * 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
GB9423419D0 (en) * 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
ES2191721T3 (en) * 1994-12-16 2003-09-16 Elan Drug Delivery Ltd RETICULATED MICROPARTICLES AND ITS USE AS THERAPEUTIC VEHICLES.

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283563A2 (en) * 1983-12-24 1988-09-28 Beecham Group Plc Novel derivatives
US4673573A (en) * 1984-01-11 1987-06-16 Beecham Group P.L.C. Novel fibrinolytic enzyme compounds
US4661471A (en) * 1984-04-10 1987-04-28 New England Deaconess Hospital Method of inhibiting and inducing human platelet aggregation
US4666884A (en) * 1984-04-10 1987-05-19 New England Deaconess Hospital Method of inhibiting binding of von Willebrand factor to human platelets and inducing interaction of platelets with vessel walls
US4703039A (en) * 1984-04-10 1987-10-27 New England Deaconess Hospital Corporation Method of producing biologically active molecules having extended life time
EP0333517A2 (en) * 1988-03-18 1989-09-20 The Rockefeller University Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
WO1990003401A1 (en) * 1988-09-30 1990-04-05 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
WO1992013547A1 (en) * 1991-02-07 1992-08-20 Alexander Mellon Eaton Drug delivery composition and method of using the same
WO1994013692A1 (en) * 1992-12-10 1994-06-23 Regents Of The University Of Minnesota Polypeptides useful for treating inflammatory disorders
EP0727225A2 (en) * 1995-02-14 1996-08-21 Sonus Pharmaceuticals, Inc. Compositions and methods for directed ultrasound imaging

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CREMERS H F M ET AL: "ALBUMIN-HEPARIN MICROSPHERES AS CARRIERS FOR CYTOSTATIC AGENTS", JOURNAL OF CONTROLLED RELEASE, vol. 12, no. 1 - 03, 1 January 1990 (1990-01-01), pages 167 - 179, XP000113382 *
KLOCZEWIAK ET AL.: "Platelet Receptor Recognition Site on Human Fibrinogen. Synthesis and Structure-Function Relationship of Peptides Corresponding to the Carboxy-Terminal Segment of the gamma Chain", BIOCHEMISTRY, vol. 23, 1984, pages 1767 - 1774, XP002061131 *
MARTODAM ET AL.: "Albumin microspheres as carrier of an inhibitor of leukocyte elastase: Potential therapeutic agent for emphysema", PROC. NATL. ACAD. SCI. USA, vol. 76, no. 5, 1979, pages 2128 - 2132, XP002061132 *
NAKAJIMA ET AL.: "Chemical Modification of Earthworm Fibrinolytic Enzyme with Human Serum Albumin Fragment and Characterization of the Protease as a Therapeutic Enzyme.", BIOSCI. BIOTECH. BIOCHEM., vol. 60, no. 2, 1996, pages 293 - 300, XP002061133 *
TROUET A ET AL: "A COVALENT LINKAGE BETWEEN DAUNORUBICIN AND PROTEINS THAT IS STABLE IN SERUM AND REVERSIBLE BY LYSOSOMAL HYDROLASES, AS REQUIRED FOR A LYSOSOMOTROPIC DRUG-CARRIER CONJUGATE: IN VITRO AND IN VIVO STUDIES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 79, January 1982 (1982-01-01), pages 626 - 629, XP002029566 *

Also Published As

Publication number Publication date
AR008680A1 (en) 2000-02-09
ES2232862T3 (en) 2005-06-01
DE69731985D1 (en) 2005-01-20
AU718956B2 (en) 2000-05-04
AU4713597A (en) 1998-05-15
EP1028752A2 (en) 2000-08-23
JP2001504813A (en) 2001-04-10
EP1028752B1 (en) 2004-12-15
US5977313A (en) 1999-11-02
WO1998017319A2 (en) 1998-04-30
ATE284714T1 (en) 2005-01-15
CA2269335C (en) 2010-05-25
CA2269335A1 (en) 1998-04-30
DE69731985T2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
WO1998017319A3 (en) Platelet substitutes and conjugation methods suitable for their preparation
MY102878A (en) Starburst conjugates
EP0329184A3 (en) Antimers and antimeric conjugation
AU7702291A (en) Dietary fiber, its process and physiologically active composition containing the same as an active ingredient
CA2279300A1 (en) Polyesteramides from cyclic monomers and surgical articles made therefrom
EP1003526A4 (en) Covalently linked n,o-carboxymethylchitosan and uses thereof
AU1056288A (en) Process for preparing storage stable, readily reconstituted frozen comestibles and frozen comestibles produced thereby
AU6145190A (en) New functional bacillus thuringiensis hybrid genes obtained by in vivo recombination
EP0754229A1 (en) Alfamin: a human serum albumin-like protein
AU2597688A (en) 2,2-difluorocyclopropylethane derivatives, process for their preparation and their use as pesticides
AU1219995A (en) Long-acting injection suspensions and a process for their preparation
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
AU2366088A (en) 2,2-dimethylchromene derivatives, process for their preparation and pharmaceutical compositions in which they are present
EP0547102A4 (en)
EP0479177A3 (en) 4- or 5-substituted pyridine-2-carboxylic acids, process for their preparation and their use as medicaments
EP0428939A3 (en) Cumarin derivatives, process for their preparation, their use and thiazolylacetic acid derivatives as intermediate
IE802033L (en) Dibenzazepine derivatives
EP0365678A4 (en) 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF.
AU6892391A (en) Toughened polyamide and compositions, process for their preparation and moulded articles made therefrom
PH27586A (en) Low molecular weight derivatives of proukokinase pharmaceutical composition containing the same and method of use thereof
GB9000908D0 (en) Procedure to prepare lithium zirconate,thus prepared lithium zirconate and intermediate product
AU6118090A (en) N,n'-bis-1,3,5-triazin-6-ylpiperazines, and process for their preparation
AU1833888A (en) 2,2-dimethylchroman-3-ol derivatives, process for their preparation and pharmaceutical compositions in which they are present
AU1638488A (en) Organo-metal compositions, preparation and use
AU627349B2 (en) Cyclic pyridine-2,4 and -2,5-dicarboxylic acid diamides, process for their preparation and their use

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97180739.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997909451

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2269335

Country of ref document: CA

Ref document number: 2269335

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/003677

Country of ref document: MX

NENP Non-entry into the national phase

Ref document number: 1998519100

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 1997909451

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1997909451

Country of ref document: EP